secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001641172-25-009462
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celularity reports 2024 revenue of $54.2M, up 138% YoY; operating loss narrows 80%
--------------------------------------------------------------------------------

- Net revenues $54.2M, up 138.1% YoY; product sales in wound care up 168.7% to $35.3M.
- Operating expenses fell 57% to $92.6M; loss from operations improved 80.1% to $38.4M.
- Received FDA Tissue Reference Group recommendation letters for new placental-derived biomaterial products.
- Cash and cash equivalents $738K at Dec 31, 2024, up from $227K prior year.
- Total assets $132.7M; stockholders' equity $8.8M at year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000164117225009462/0001641172-25-009462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000164117225009462/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer